An Open-Label One-way Interaction Clinical Trial to Evaluate the Pharmacokinetic Interactions Between GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Aug 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Emtricitabine/tenofovir alafenamide (Primary) ; Fipravirimat (Primary)
Indications HIV infections
Focus Pharmacokinetics
Sponsors ViiV Healthcare

22 Mar 2021 Results assessing pharmacokinetics, safety and tolerability of GSK3640254 and Tenofovir Alafenamide/Emtricitabine in healthy subjects, published in the Antimicrobial Agents and Chemotherapy.
03 Jun 2019 Status changed from not yet recruiting to completed.
14 Feb 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com